New options for medical therapy and risk scoring systems containing molecular data are
leading to increased complexity in the management of patients with myelofibrosis. To inform …

The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN)
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …

Advances in understanding the pathogenesis and molecular landscape of myelofibrosis
have occurred over the last decade. Treating physicians now have access to an ever …

Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for
myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF …

Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative treatment
for myelofibrosis. However, the optimal conditioning regimen either with reduced-intensity …

The number of patients with myelofibrosis (MF) undergoing an allogeneic hemopoietic stem
cell transplantation (HSCT) is increasing: in the analysis of the European Group for Blood …

We report the results from a multicenter retrospective study of 69 adult patients who
underwent haploidentical blood or marrow transplantation (haplo-BMT) with post …

Haploidentical donors offer a potentially readily available donor, especially for non-White
patients, for hematopoietic cell transplantation (HCT). In this North American collaboration …

We aimed to compare outcomes following treosulfan (TREO) or busulfan (BU) conditioning
in a large cohort of myelofibrosis (MF) patients from the EBMT registry. A total of 530 patients …

Introduction The approach to myelofibrosis (MF) has been revolutionized in recent years,
overcoming the traditional therapies, often not very effective. Janus kinase inhibitors (JAKi …